References
- SelvinEBurnettALPlatzEAPrevalence and risk factors for erectile dysfunction in the USAm J Med200712015115717275456
- LindauSTSchummLPLaumannEOLevinsonWO’MuircheartaighCAWaiteLJA study of sexuality and health among older adults in the United StatesN Engl J Med200735776277417715410
- CoronaGLeeDMFortiGEMAS Study GroupAge-related changes in general and sexual health in middle-aged and older men: results from the European male ageing studyJ Sex Med201071362138019929914
- ShamloulRGhanemHErectile dysfunctionLancet201338115316523040455
- SungHHAhnJSKimJJChooSHHanDHLeeSWThe role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitorsAndrology20142455024194017
- RaheemAAKellPPatient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafilPatient Prefer Adherence200939910419936151
- AmendolaEViagra to go generic in 2017 according to Pfizer agreement2013 Available from: cbsnews com [serial online]. Available from: CBS NewsAccessed February 14, 2015
- PhillipsDJPfizer’s Expiring Viagra Patent Adversely Affects Other Drugmakers Too Available from: Forbes.com. December 20, 2013. February 13, 2015 [Ref Type: Online Source].
- RosenRCPadma-NathanHShabsighRSaikaliKWatkinsVPullmanWDetermining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home studyJ Sex Med2004119320016422974
- KyleJABrownDAHillJKAvanafil for erectile dysfunctionAnn Pharmacother2013471312132024259695
- BurkeRMEvansJDAvanafil for treatment of erectile dysfunction: review of its potentialVasc Health Risk Manag2012851752322973106
- GoldsteinIMcCulloughARJonesLAA randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunctionJ Sex Med201291122113322248153
- BelkoffLHMcCulloughAGoldsteinIAn open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunctionInt J Clin Pract20136733334123521325
- HellstromWJKaminetskyJBelkoffLHEfficacy of avanafil fifteen minutes after dosing in men with erectile dysfunction: a randomized, double-blind, placebo-controlled studyJ Urol2015194248549225591992
- YuanJZhangRYangZComparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysisEur Urol20136390291223395275
- SmithWBMcCaslinIRGokceAMandavaSHTrostLHellstromWJPDE5 inhibitors: considerations for preference and long-term adherenceInt J Clin Pract20136776878023869678
- CostaPGrandmottetGMaiHDDroupySImpact of a first treatment with phosphodiesterase inhibitors on men and partners’ quality of sexual life: results of a prospective study in primary careJ Sex Med2013101850186023679019
- Martin-MoralesAHaroJMBeardsworthABertschJKontodimasSTherapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS)Eur Urol20075154155017084518
- CairoliCReyesLAHennegesCSorsaburuSPDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational studyInt Braz J Urol20144039039925010306
- TsujimuraAKiuchiHSodaTSexual life of Japanese patients with erectile dysfunction taking phosphodiesterase type 5 inhibitors: an Internet survey using the Psychological and Interpersonal Relationship Scales-Short Form questionnaireInt J Urol20142182182524661267
- BuvatJBüttnerHHatzimouratidisKAdherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunctionJ Sex Med2013101592160223551622
- Martín-MoralesAGraziottinAJaoudéGBImprovement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, Placebo-controlled studyJ Sex Med201182831284021679304